secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akebia Therapeutics, Inc. (AKBA)
CIK:        0001517022
Form:       8-K
Filed at:   2025-10-28T23:59:59+00:00
Accession:  0001517022-25-000040
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akebia abandons Vafseo broad label pursuit for non-dialysis CKD after FDA alignment failure
--------------------------------------------------------------------------------

- Akebia will not initiate the VALOR trial for vadadustat in late-stage CKD not on dialysis after FDA feedback.
- FDA indicated the trial would require significantly more patients and meaningfully more time and cost.
- Akebia does not expect to pursue a broad label for Vafseo for non-dialysis dependent CKD patients.
- Vafseo remains approved only for anemia in dialysis-dependent CKD patients; launched in U.S. Jan 2025.
- Akebia is encouraged by FDA discussion on smaller subgroups but no specific path forward yet.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517022/000151702225000040/0001517022-25-000040-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517022/000151702225000040/akba-20251028.htm
  HTML page:      https://secwatch.observer/filing/0001517022-25-000040

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer